# An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

> **NCT00738699** · PHASE2 · TERMINATED · sponsor: **Morphotek** · enrollment: 415 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** MORAb-003 (farletuzumab)
- **DRUG:** 0.9% Saline
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT00738699
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 415 (ACTUAL)
- **Why stopped:** study did not meet pre-specified criteria for continuation following interim futility analysis
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738699, "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00738699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*